Literature DB >> 8633251

Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.

Y Pommier1.   

Abstract

Topoisomerase I enzymes are ubiquitous and play a pivotal role in DNA transcription, replication, and repair. The eukaryotic form of this enzyme is highly conserved and its inhibition leads to accumulation of DNA strand breaks ('cleavable complexes') and ultimately cell death. An understanding of the role of eukaryotic topoisomerase I has led researchers to identify this enzyme as a potential target for anticancer therapy. Indeed, topoisomerase I is inhibited by samptothecin (isolated from a plant extract), and derivatives of this agent are being developed with improved physicochemical and pharmacologic characteristics. These agents may provide a new dimension to chemotherapy through their novel mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633251

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  19 in total

1.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

2.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

3.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

4.  DNA replication but not nucleotide excision repair is required for UVC-induced replication protein A phosphorylation in mammalian cells.

Authors:  G Rodrigo; S Roumagnac; M S Wold; B Salles; P Calsou
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 5.  Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

Authors:  L R Wiseman; A Markham
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

6.  Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Alexandra Ioanoviciu; Smitha Antony; Glenda Kohlhagen; Keli Agama; Melinda Hollingshead; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

7.  Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors.

Authors:  Kim A Lopez; Aaron M Tannenbaum; Marcela C Assanah; Katy Linskey; Jonathan Yun; Alayar Kangarlu; Orlando D Gil; Peter Canoll; Jeffrey N Bruce
Journal:  Cancer Res       Date:  2011-04-04       Impact factor: 12.701

8.  A knockdown with smoke model reveals FHIT as a repressor of Heme oxygenase 1.

Authors:  Jennifer A Boylston; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.

Authors:  W Hiraoka; N Vazquez; W Nieves-Neira; S J Chanock; Y Pommier
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures.

Authors:  Smitha Antony; Paola B Arimondo; Jian-Sheng Sun; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2004-10-04       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.